Tests LNS8801 alone or with pembrolizumab in advanced melanoma
Tests a new drug, LNS8801, with or without pembrolizumab, in adults with melanoma.
Key facts
- Who runs it
- Linnaeus Therapeutics, Inc.
- Where
- Albuquerque, Aurora, Boston, Denver, Newport Beach, Philadelphia, San Francisco, Stanford, and Tampa, United StatesSee the 9 sites
- Trial code
- Registry title
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 135 people, planned
- Started
- 6 Aug 2025
- Expected to end
- Feb 2031
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- LNS8801
- Pembrolizumab
- Chemotherapy (dacarbazine or temozolomide)
- Immunotherapy (Pembrolizumab)
- Immunotherapy (nivolumab and relatlimab)
- Immunotherapy (ipilimumab and nivolumab)
- Record updated
- 22 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma of the skin that cannot be removed by surgery or has spread, and that kept growing after anti-PD-1 treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed cutaneous melanoma that cannot be removed by surgery and/or has spread, with measurable disease
- Earlier treatment
- The melanoma must have progressed on an anti-PD-1 antibody, given alone or with other therapies. People must also have had an anti-CTLA-4 and/or BRAF treatment, or not be able to have it or have declined it.
- Biomarker or test result
- 2 copies of the fully functional form of the GPER protein-coding sequence
Main reasons for not taking part
- Blue nevus, mucosal, acral lentiginous or uveal/ocular/choroidal melanoma
- Anti-cancer or investigational treatment within 4 weeks of the first dose
- Radiotherapy within 2 weeks of starting study drug
- Allogeneic tissue or solid organ transplant
- Unstable autoimmune or immunodeficiency disease
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Confirmed unresectable and/or metastatic cutaneous melanoma
- 2 copies of the fully functional form of GPER protein-coding sequence
- Eligible for and willing to receive 1 or more of the physician's choice (PC) therapies
- Able to swallow tablets
- Progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other therapies
- Received an anti-CTLA-4 and/or BRAF containing regimen or is not eligible for or has declined anti-CTLA-4 and/or BRAF therapy prior to and for this study
- Measurable disease
- Eastern Cooperative Oncology Group Performance Status of 0 to 1
Who cannot take part
- Previous anti-cancer or investigational drug/device treatment within 4 weeks of the first dose of study drug
- Radiotherapy within 2 weeks of starting study drug
- Allogeneic tissue/solid organ transplant
- Other concurrent health issues that would make participation or completion of the study difficult
- Prior reaction to anti PD-1 therapy that would make treatment with pembrolizumab unadvisable
- Unstable autoimmune or immunodeficiency disease
- Blue nevus subtype, mucosal, acral lentiginous, or uveal/ocular/choroidal Melanoma
- Other protocol-defined inclusion/exclusion criteria may apply
Where in United States
- University of New MexicoAlbuquerque, United StatesContact: Moises TurquieTaking people
- University of Colorado AnschutzAurora, United StatesContact: Sapna PatelTaking people
- Dana FarberBoston, United StatesContact: Justine CohenTaking people
- University of ColoradoDenver, United StatesContact: Kathy PrinzTaking people
- USC Newport BeachNewport Beach, United StatesContact: Samantha KwanTaking people
- UPennPhiladelphia, United StatesContact: Tara MitchellTaking people
- UCSFSan Francisco, United StatesContact: Katy TsaiTaking people
- StanfordStanford, United StatesContact: V DingankarTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Indra HeronTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor.
Read full original descriptionShow less
135 patients will be randomly (like flipping a coin) placed in 3 treatment groups.
In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years.
In the second group (LNS8801 + pembrolizumab) - Patients will take 125mg tablet of LNS8801 by mouth once per day plus 200 mg of pembrolizumab by IV infusion once every 3 weeks for up to 2 years.
In the third group, called Physician's Choice (PC), patients will receive chemotherapy (dacarbazine or temozolomide) or immunotherapy (pembrolizumab, nivolumab/relatlimab or nivolumab/ipilimumab) as determined by their treating physician.
How often the patient visits the clinic visits will depend on the treatment group. Besides returning to the clinic for treatment, the patient will undergo periodic safety assessments and other required study procedures such as imaging assessments.
The 3 groups in the trial
- LNS8801 MonotherapyTreatment being tested
125 mg LNS8801 by mouth every day
Treatment: LNS8801
- LNS8801 + PembrolizumabTreatment being tested
125 mg LNS8801 by mouth every day plus 200 mg Pembrolizumab by IV infusion once every 3 weeks.
Treatment: LNS8801 and Pembrolizumab
- Physician's ChoiceExisting treatment, for comparison
patients may receive chemotherapy or immunotherapy as determined by physician.
Treatment: Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolumab and relatlimab), and Immunotherapy (ipilimumab and nivolumab)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
- Plain-language title
- Tests LNS8801 alone or with pembrolizumab in advanced melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 April 2026